PL3495352T3 - Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie - Google Patents

Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie

Info

Publication number
PL3495352T3
PL3495352T3 PL17842980T PL17842980T PL3495352T3 PL 3495352 T3 PL3495352 T3 PL 3495352T3 PL 17842980 T PL17842980 T PL 17842980T PL 17842980 T PL17842980 T PL 17842980T PL 3495352 T3 PL3495352 T3 PL 3495352T3
Authority
PL
Poland
Prior art keywords
preparation
receptor antagonist
androgen receptor
crystal forms
crystal
Prior art date
Application number
PL17842980T
Other languages
English (en)
Inventor
Minhua Chen
Yanfeng Zhang
Jiaoyang LI
Kaiqiang YAN
Qiyue LIU
Xiaoyu Zhang
Original Assignee
Crystal Pharmaceutical (Suzhou) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical (Suzhou) Co., Ltd. filed Critical Crystal Pharmaceutical (Suzhou) Co., Ltd.
Publication of PL3495352T3 publication Critical patent/PL3495352T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17842980T 2016-08-26 2017-08-25 Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie PL3495352T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610737732 2016-08-26
CN201610871736 2016-09-30
CN201610876685 2016-10-08
PCT/CN2017/099036 WO2018036558A1 (zh) 2016-08-26 2017-08-25 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
EP17842980.9A EP3495352B1 (en) 2016-08-26 2017-08-25 Crystal forms of an androgen receptor antagonist, preparation method and use thereof

Publications (1)

Publication Number Publication Date
PL3495352T3 true PL3495352T3 (pl) 2021-08-02

Family

ID=61246439

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17842980T PL3495352T3 (pl) 2016-08-26 2017-08-25 Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie

Country Status (16)

Country Link
US (1) US10815221B2 (pl)
EP (1) EP3495352B1 (pl)
JP (1) JP6716023B2 (pl)
CN (1) CN109641851B (pl)
CY (1) CY1124083T1 (pl)
DK (1) DK3495352T3 (pl)
ES (1) ES2869882T3 (pl)
HR (1) HRP20210667T1 (pl)
HU (1) HUE053958T2 (pl)
LT (1) LT3495352T (pl)
PL (1) PL3495352T3 (pl)
PT (1) PT3495352T (pl)
RS (1) RS61773B1 (pl)
SI (1) SI3495352T1 (pl)
SM (1) SMT202100251T1 (pl)
WO (1) WO2018036558A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121181479A (zh) 2017-03-07 2025-12-23 奥赖恩公司 结晶药物产品的制备
CN110944979B (zh) * 2017-08-09 2023-05-12 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
JP2021515040A (ja) * 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
JP2022505033A (ja) * 2018-10-18 2022-01-14 ジェムフィアー セラピューティクス インコーポレイテッド ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
EP4486727B1 (en) 2022-02-28 2026-02-25 Química Sintética, S.A. Crystalline form of darolutamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2012143599A1 (en) * 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
EP3250554B1 (en) * 2015-01-30 2022-05-18 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form
CN110944979B (zh) 2017-08-09 2023-05-12 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物

Also Published As

Publication number Publication date
ES2869882T3 (es) 2021-10-26
JP2019526570A (ja) 2019-09-19
SMT202100251T1 (it) 2021-05-07
US20200239450A1 (en) 2020-07-30
CN109641851B (zh) 2022-09-02
DK3495352T3 (da) 2021-05-03
HRP20210667T1 (hr) 2021-05-28
EP3495352A4 (en) 2019-06-12
PT3495352T (pt) 2021-05-03
CN109641851A (zh) 2019-04-16
RS61773B1 (sr) 2021-05-31
LT3495352T (lt) 2021-06-10
EP3495352B1 (en) 2021-01-27
SI3495352T1 (sl) 2021-08-31
HUE053958T2 (hu) 2021-08-30
EP3495352A1 (en) 2019-06-12
JP6716023B2 (ja) 2020-07-01
US10815221B2 (en) 2020-10-27
WO2018036558A1 (zh) 2018-03-01
CY1124083T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
IL265806A (en) Compounds and Methods for Targeted Reduction of Androgen Receptor
SMT202100251T1 (it) Forme cristalline di un antagonista del recettore degli androgeni, metodo di preparazione e suo uso
PT3470400T (pt) Formas cristalinas de ozanimod e cloridrato de ozanimod, e processos para a preparação das mesmas
EP3094346A4 (en) Vista antagonist and methods of use
ZA201706671B (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
ZA201701216B (en) Improved locking apparatus, locking member, and method of use
IL284005A (en) Glucocorticoid receptor inhibitors
ZA201805496B (en) Somatostatin receptor antagonist compounds and methods of using the same
PL3216791T3 (pl) Substancja polimorficzna chlorowodorku jonkenafilu, sposób jej wytwarzania oraz jej kompozycja i zastosowanie
GB201500638D0 (en) Scaffold fitting means and method of use thereof
HUE055891T2 (hu) A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja
HUE050459T2 (hu) Androgénreceptor-gátló kristályformája és annak elõállítási eljárása
EP3277665A4 (en) Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof
EP3135669A4 (en) Oxazolidine-based compound and selective androgen receptor agonist comprising same
GB201508694D0 (en) Construction apparatus and method of use thereof
AU2014903404A0 (en) Receptor dimerization domain and method of use
GB201403200D0 (en) Cushion means and method of use thereof